EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Nanoparticle‐Mediated Targeted Protein Degradation: An Emerging Therapeutics Technology

Andrew G Baker, Adrian Pui Ting Ho, Laura S Itzhaki, Ljiljana Fruk

Angewandte Chemie International Edition · 07.07.2025 · 64 (28)

DOI: 10.1002/anie.202503958 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Angewandte Chemie International Edition, online erschienen am 09.05.2025. Verfasst von Andrew G Baker und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, University of Cambridge, Tennis Court Road, Cambridge, CB2 1PD, UK. Hauptthemen laut MEDLINE: Nanoparticles, Proteins, Proteolysis. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 144 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: EPSRC, EPSRC NanoDTC, Engineering and Physical Sciences Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Targeted protein degradation (TPD) has emerged as a transformative therapeutic strategy for eliminating disease‐associated proteins, with relevance across disorders ranging from cancer to neurodegeneration. Since its inception nearly two decades ago, TPD has attracted strong academic and commercial interest, with multiple candidates advancing into clinical trials. Despite this progress, the field faces persistent challenges, including limited solubility, poor cellular uptake, and unpredictable structure–activity relationship of small‐molecule degraders, which complicate rational design. To address these limitations, alternative platforms such as nanoparticle‐mediated protein degraders (NanoPDs) have gained attention. First reported 17 years ago, NanoPDs harness a diverse array of materials, degradation mechanisms, and linker chemistries to achieve protein clearance through novel pathways. Although promising, their clinical translation remains constrained by barriers such as lysosomal entrapment, protein corona formation, and biocompatibility concerns. In this review, we present a comprehensive overview of the current landscape of nanoparticle‐mediated TPD. We emphasize the design principles underlying nano–bio interfaces and explore the role of proximity‐induced biology as a mechanism for orchestrating protein interactions. Finally, we highlight critical challenges and key questions that must be addressed to fully realize the therapeutic potential of NanoPDs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NanoparticlesProteinsProteolysisHumansAnimals

Stichwörter der Autor:innen

Lysosome‐targeting chimeraNanomedicinePROTACProteolysis‐targeting chimeraTargeted protein degradation

Substanzen

Proteins

Autor:innen und Institutionen

  • Department of Pharmacology, University of Cambridge, Tennis Court Road, Cambridge, CB2 1PD, UK.
  • Department of Chemical Engineering and Biotechnology, University of Cambridge, Philippa Fawcett Drive, Cambridge, CB3 0AS, UK.

Förderung

  • EPSRC
  • EPSRC NanoDTC
  • Engineering and Physical Sciences Research Council

Zitieren

APA

Baker, A. G., Ho, A. P. T., Itzhaki, L. S., & Fruk, L. (2025). Nanoparticle‐Mediated Targeted Protein Degradation: An Emerging Therapeutics Technology. Angewandte Chemie International Edition, 64(28). https://doi.org/10.1002/anie.202503958

Vancouver

Baker AG, Ho APT, Itzhaki LS, Fruk L. Nanoparticle‐Mediated Targeted Protein Degradation: An Emerging Therapeutics Technology. Angewandte Chemie International Edition. 2025;64(28). doi:10.1002/anie.202503958

BibTeX
@article{Baker2025,
  author = {Baker, Andrew G and Ho, Adrian Pui Ting and Itzhaki, Laura S and Fruk, Ljiljana},
  title = {Nanoparticle‐Mediated Targeted Protein Degradation: An Emerging Therapeutics Technology},
  journal = {Angewandte Chemie International Edition},
  year = {2025},
  volume = {64},
  number = {28},
  doi = {10.1002/anie.202503958}
}
Kostenlos starten →